Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations.

Autor: Lorenz S; Department of Tumor Biology, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway.; Norwegian Cancer Genomics Consortium, Norway., Barøy T; Department of Tumor Biology, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway.; Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Sun J; Genomics Core Facility, Department of Core Facilities, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway.; Norwegian Cancer Genomics Consortium, Norway., Nome T; Department of Molecular Oncology, Institute for Cancer research, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway.; Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Vodák D; Department of Tumor Biology, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway., Bryne JC; Department of Tumor Biology, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway.; Genomics Core Facility, Department of Core Facilities, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway., Håkelien AM; Department of Tumor Biology, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway., Fernandez-Cuesta L; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany.; Genetic Cancer Susceptibility Group, International Agency for Research on Cancer (IARC-WHO), Lyon, France., Möhlendick B; Institute for Human Genetics, University Hospital Düsseldorf, Düsseldorf, Germany., Rieder H; Institute for Human Genetics, University Hospital Düsseldorf, Düsseldorf, Germany., Szuhai K; Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, The Netherlands., Zaikova O; Clinic for Cancer, Surgery and Transplantation, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway., Ahlquist TC; Department of Molecular Oncology, Institute for Cancer research, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway.; Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Thomassen GO; Department of Molecular Oncology, Institute for Cancer research, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway.; Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Skotheim RI; Department of Molecular Oncology, Institute for Cancer research, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway.; Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Lothe RA; Department of Molecular Oncology, Institute for Cancer research, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway.; Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Tarpey PS; Wellcome Trust Sanger Institute, Hinxton, UK., Campbell P; Wellcome Trust Sanger Institute, Hinxton, UK., Flanagan A; Royal National Orthopaedic Hospital, Middlesex, UK.; UCL Cancer Institute, University College London, London, UK., Myklebost O; Department of Tumor Biology, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway.; Norwegian Cancer Genomics Consortium, Norway., Meza-Zepeda LA; Department of Tumor Biology, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway.; Genomics Core Facility, Department of Core Facilities, Oslo University Hospital, Norwegian Radium Hospital, Oslo, Norway.; Norwegian Cancer Genomics Consortium, Norway.

Publikováno v: Oncotarget [Oncotarget] 2016 Feb 02; Vol. 7 (5), pp. 5273-88.

Genome-wide, whole mount in situ analysis of transcriptional regulators in zebrafish embryos.

Autor: Armant O; Institute of Toxicology and Genetics, Karlsruhe Institute of Technology, Postfach 3640, 76021 Karlsruhe, Germany., März M, Schmidt R, Ferg M, Diotel N, Ertzer R, Bryne JC, Yang L, Baader I, Reischl M, Legradi J, Mikut R, Stemple D, van IJcken W, van der Sloot A, Lenhard B, Strähle U, Rastegar S

Publikováno v: Developmental biology [Dev Biol] 2013 Aug 15; Vol. 380 (2), pp. 351-62. Date of Electronic Publication: 2013 May 14.

A novel complex, RUNX1-MYEF2, represses hematopoietic genes in erythroid cells.

Autor: van Riel B; Department of Cell Biology and Center for Biomedical Genetics, Erasmus Medical Center, Rotterdam, Netherlands., Pakozdi T, Brouwer R, Monteiro R, Tuladhar K, Franke V, Bryne JC, Jorna R, Rijkers EJ, van Ijcken W, Andrieu-Soler C, Demmers J, Patient R, Soler E, Lenhard B, Grosveld F

Publikováno v: Molecular and cellular biology [Mol Cell Biol] 2012 Oct; Vol. 32 (19), pp. 3814-22. Date of Electronic Publication: 2012 Jul 16.

Dynamic long-range chromatin interactions control Myb proto-oncogene transcription during erythroid development.

Autor: Stadhouders R; Department of Cell Biology, Erasmus MC, Rotterdam, The Netherlands., Thongjuea S, Andrieu-Soler C, Palstra RJ, Bryne JC, van den Heuvel A, Stevens M, de Boer E, Kockx C, van der Sloot A, van den Hout M, van Ijcken W, Eick D, Lenhard B, Grosveld F, Soler E

Publikováno v: The EMBO journal [EMBO J] 2012 Feb 15; Vol. 31 (4), pp. 986-99. Date of Electronic Publication: 2011 Dec 13.

A systems approach to analyze transcription factors in mammalian cells.

Autor: Soler E; Department of Cell Biology, Erasmus Medical Center, Dr. Molewaterplein 50, Rotterdam, The Netherlands. e.soler@erasmusmc.nl, Andrieu-Soler C, Boer Ed, Bryne JC, Thongjuea S, Rijkers E, Demmers J, van IJcken W, Grosveld F

Publikováno v: Methods (San Diego, Calif.) [Methods] 2011 Feb; Vol. 53 (2), pp. 151-62. Date of Electronic Publication: 2010 Aug 10.